At a glance
- Originator Pharmacia Corporation
- Class Amino acids; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action Kynurenine 3-monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Seizures
Most Recent Events
- 05 Oct 1998 No-Development-Reported for Neurological disorders in Italy (Unknown route)
- 05 Oct 1998 No-Development-Reported for Seizures in Italy (Unknown route)
- 24 Jan 1997 Preclinical development for Neurological disorders in Italy (Unknown route)